Skip to content

DZX Mediated Insulin Suppression in Obese Men

Diazoxide-mediated Insulin Suppression in Hyperinsulinemic Obese Men, Part III

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00631033
Enrollment
51
Registered
2008-03-07
Start date
2008-07-31
Completion date
2011-12-31
Last updated
2014-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Keywords

obesity, hyperinsulinism, diazoxide, metformin

Brief summary

The purpose of this study is to determine whether there is an additive effect of metformine on the weight reduction of obese hyperinsulinemic men who are treated with diazoxide.

Interventions

DRUGPlacebo
DRUGMetformin + Diazoxide

Sponsors

Rijnstate Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
MALE
Age
25 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* male * age 25-50 years * BMI 30-35 kg/m2 * stable body weight during 3 months before the start of the study * glucose \<= 6.0 mmol/L * C-peptide \>= 1.0 nmol/L * HbA1c \<= 6.0%

Exclusion criteria

* comorbidity * medication * serum creatinine \> 120 micromol/L * liver enzymes \> 2 times upper limits of normal * gout * alcohol use \> 2 alcoholic drinks a day * drug abuse * cessation of smoking less than 6 months ago

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026